Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has received an average rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the […]

Related Keywords

United States , William Blair , Marquette Asset Management , Jefferies Financial Group , Nektar Therapeutics , Sg Americas Securities , Nasdaq , Citigroup Inc , Mackenzie Financial Corp , Cm Management , Get Free Report , Marketbeat Ratings , Financial Group , Asset Management , Get Free , Nektar Therapeutics Daily , Nasdaq Nktr , Nktr , Medical , 64026810 , Ratings , Consensus ,